These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21478189)

  • 1. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Tatsuki Y; Yano T; Yoshinari T; Abe T; Koike T
    Ann Rheum Dis; 2011 Jul; 70(7):1208-15. PubMed ID: 21478189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.
    Edrees AF; Misra SN; Abdou NI
    Clin Exp Rheumatol; 2005; 23(4):469-74. PubMed ID: 16095114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
    St Clair EW; Wagner CL; Fasanmade AA; Wang B; Schaible T; Kavanaugh A; Keystone EC
    Arthritis Rheum; 2002 Jun; 46(6):1451-9. PubMed ID: 12115174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
    Smolen JS; Han C; van der Heijde DM; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Aletaha D; Baker D; Han J; Bala M; St Clair EW;
    Ann Rheum Dis; 2009 Jun; 68(6):823-7. PubMed ID: 18593759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
    Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
    Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
    Ariza-Ariza R; Navarro-Sarabia F; Hernández-Cruz B; Rodríguez-Arboleya L; Navarro-Compán V; Toyos J
    Rheumatology (Oxford); 2007 Mar; 46(3):529-32. PubMed ID: 17012439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
    Saleem B; Mackie S; Quinn M; Nizam S; Hensor E; Jarrett S; Conaghan PG; Emery P
    Ann Rheum Dis; 2008 Aug; 67(8):1178-80. PubMed ID: 18234715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.
    Kvalvik AG; Lefsaker L; Dyvik S; Brun JG
    Joint Bone Spine; 2007 Dec; 74(6):606-11. PubMed ID: 17900958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
    Sidiropoulos P; Bertsias G; Kritikos HD; Kouroumali H; Voudouris K; Boumpas DT
    Ann Rheum Dis; 2004 Feb; 63(2):144-8. PubMed ID: 14722202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.